Explanatory Note
(This note is not part of the Order)
This Order makes a technical correction to article 1(5) of the Prescription Only Medicines (Human Use) Order 1997 and amends Schedule 1 to that Order (which specifies substances which, if included in medicinal products, make them prescription only medicines, and exemptions from the restrictions in section 58(2) on sale and supply of prescription only medicines) in order to provide—
(a)for the amendment of the conditions under which medicinal products containing Adrenaline, Fluconazole, Hydrocortisone Acetate, Stannous Fluoride and Terbinafine Hydrochloride may be sold or supplied otherwise than as prescription only medicines;
(b)that medicinal products containing Clobetasone Butyrate, Fenticonazole Nitrate and Prochlorperazine Maleate may be sold or supplied otherwise than as prescription only medicines on the conditions specified;
(c)for the insertion in Schedule 1 of the substances Amisulpride, Balsalazide Sodium, Benserazide, Brimonidine Tartrate, Carbasalate Calcium, Cefdinir, Cerivastatin Sodium, Donepezil Hydrochloride, Fexofenadine Hydrochloride, Flutrimazole, Irbesartan, Levofloxacin, Mercaptamine Bitartrate, Modafinil, Naratriptan Hydrochloride, Pramipexole Hydrochloride, Reboxetine Mesilate, Sertindole, Temocapril Hydrochloride, Testosterone, Valsartan.
An assessment of the cost to business of complying with this Order has been made, a copy of which has been placed in the libraries of both Houses of Parliament. Further copies may be obtained from the Department of Health, Medicines Control Agency, Information Centre, Room 10-202 Market Towers, 1 Nine Elms Lane, London SW8 5NQ.